biOasis Technologies Ord Shs V.BTI.H

So do we assume the JNJ option expired?

[zwerp2000]

The company is responsible for releasing material news. We have heard nothing so I have to presume the option expired with JNJ. Maybe it will be a short footnote in one of their disorganized/messy financial statements. I am sure if BTI thought JNJ was going to move forward, they would not have tried to sell for peanuts. So prothena passed, presumably JNJ passed, Chiesi is doing nothing with the platform. Amazing how all of these big companies are passing on such an amazing platform. Why is that? Why can't these highly educated people see what JD and prophet see? I guess jd/prophet are just much smarter than they are, right?

[Boomskid]

The J&J agreement was likely all about J&J exploring something with xB3 and about xB3. Such agreements usually prevent the licensee from doing anything beyond that. A new agreement is required to do more work and to advance anything worth advancing.   So how might such an agreement resolve itself? Was xB3 successful in its job of transporting its J&J payload? (Almost

[G1945V]

"If J&J enters a deal with Bioasis then we have an answer." JD, this deal with J&J ( Janssen) was announced on April 11, 2022. Were we told when the option to research and develop products based on the xB3 platform runs out?  G1945V 

[Boomskid]

The latest MD&A has details, G1945V, on Page 10. jd

[G1945V]

MD&A dated January 19, 2023: "On April 11, 2022, the Company entered into a research collaboration with Janssen Biotech, Inc., one of the Pharmaceutical Companies of Johnson & Johnson. Under the terms of the agreement, the Company received a non-refundable, upfront payment of US$100,000. In addition, the Company will receive milestone payments based on the

[prophetoffactz]

"Janssen will have the option to research, develop and commercialize novel products based on the Company’s xB 3 technology." MD&A  Note what jd said: "The J&J agreement was likely all about J&J exploring something with xB3 and about xB3. Such agreements usually prevent the licensee from doing anything beyond that. A new agreement is required to do

[Boomskid]

Yes, the MD&A and I are in agreement. J&J/Janssen have an option to sign another agreement to advance whatever they're working on. Without exercising the option by extending the current one or entering a new one, J&JJanssen likely won't be able to do anything further. (That's the meaning of "option.") My continuing point is that if both sides want to advance the

[fuzzyjr]

"Bioasis cannot be counted upon currently to back up any agreements they might enter" who ya going to count on then? b teams plan c or d?? Yep, "precarious position" to say the least!!  Going to take a fair amount of time & something special to happen to get this thing going again.I'll watch from the sidelines until the dust settles, just like the